Key result
Concomitant CABG, AVR, and MVR achieves ~93% 30-day survival in rheumatic heart disease and CAD.
Cohort (n=103)
No
Concomitant CABG, AVR, and MVR for patients with rheumatic heart disease and CAD provides acceptable short- and mid-term survival and symptomatic amelioration.
Answers are grounded in this paper and cite their sources.
May guide surgical decisions in rheumatic heart disease with CAD; leaves open need for randomized confirmation of benefit.
OBJECTIVES: It has been reported that the short-term mortality of concomitant aortic and mitral valve replacement (AVR and MVR) is considerable and concomitant coronary artery bypass graft (CABG) has adverse effects on the survival of patients with valve replacement surgery. We summarize the short- and mid-term outcome after concomitant CABG, AVR and MVR in our centre. METHODS: Between 2003 and 2013, 103 patients (68 males, 35 females, age: 60.1 ± 10.1 years) underwent CABG, AVR and MVR for rheumatic heart disease (RHD) and coronary artery disease (CAD). The median follow-up was 47.6 months. Most of the patients were asymptomatic at rest. We analysed demographic, clinical and operative data of patients to define independent predictors of overall survival, cardiac event-free survival as well as cardiac death. RESULTS: The rate of 30-day survival was 93% (n = 96). The corresponding rates of overall survival and cardiac event-free survival and the cumulative incidence rate of cardiac death at 1 year were 80.2, 77.3 and 10.9%; the same at 4 years were 73.7, 64.6 and 15.8%. The corresponding freedom rates from anticoagulation-associated major haemorrhage; a composite of major bleeding events, thromboemboli and valvular thrombosis; cardiac rehospitalization; major adverse valve-associated events; and significant malfunction of the prosthetic valve were 96.2, 95.3, 94.7, 81.6 and 97.7% at 1 year. The corresponding freedom rates from anticoagulation-associated major haemorrhage; a composite of major bleeding events, thromboemboli and valvular thrombosis; cardiac rehospitalization; major adverse valve-associated events; and significant malfunction of the prosthetic valve were 93.5, 91.0, 91.4, 73.5 and 95.5% at 4 years. The independent predictors of overall survival were age, cigarette smoking, chronic kidney diseases and balloon pump insertion. The independent predictors of cardiac event-free survival were age and previous myocardial infarction, while age, cigarette smoking, history of cerebrovascular accident and balloon pump insertion were the independent predictors of cardiac death. CONCLUSIONS: Concomitant CABG, AVR and MVR for rheumatic heart disease accompanied by CAD appear to have acceptable short- and mid-term outcomes with symptomatic amelioration.
No takes yet. Share an insight, caveat, or question.
Davarpasand et al. (2015) conducted a cohort in Rheumatic heart disease and coronary artery disease (n=103). Concomitant CABG, AVR, and MVR was evaluated on 30-day survival. Concomitant CABG, AVR, and MVR for rheumatic heart disease and CAD demonstrated a 30-day survival rate of 93% and a 4-year overall survival rate of 73.7%.
Synapse has enriched 10 related papers. Consider them for comparative context: